Nebulized Therapies in COPD: Past, Present, and the Future
Open Access
- 1 July 2020
- journal article
- review article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 1665-1677
Abstract
Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating patients with chronic obstructive pulmonary disease (COPD). Inhalation devices consist of nebulizers and handheld inhalers, such as dry-powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Although pMDIs, DPIs and SMIs may be appropriate for most patients with COPD, certain patient populations may have challenges with these devices. Patients who have cognitive, neuromuscular, or ventilatory impairments (and receive limited assistance from caregivers), as well as those with suboptimal peak inspiratory flow may not derive the full benefit from handheld inhalers. A considerable number of patients are not capable of producing a peak inspiratory flow rate to overcome the internal resistance of DPIs. Furthermore, patients may have difficulty coordinating inhalation with device actuation, which is required for pMDIs and SMIs. However, inhalation devices such as spacers and valved holding chambers can be used with pMDIs to increase the efficiency of aerosol delivery. Nebulized treatment provides patients with COPD an alternative administration route that avoids the need for inspiratory flow, manual dexterity, or complex hand-breath coordination. The recent approval of two nebulized long-acting muscarinic antagonists has added to the extensive range of nebulized therapies in COPD. Furthermore, with the availability of quieter and more portable nebulizer devices, nebulization may be a useful treatment option in the management of certain patient populations with COPD. The aim of this narrative review was to highlight recent updates and the treatment landscape in nebulized therapy and COPD. We first discuss the pathophysiology of patients with COPD and inhalation device considerations. Second, we review the updates on recently approved and newly marketed nebulized treatments, nebulized treatments currently in development, and technological advances in nebulizer devices. Finally, we discuss the current applications of nebulized therapy in patients with COPD.Keywords
This publication has 68 references indexed in Scilit:
- Considerations for managing chronic obstructive pulmonary disease in the elderlyClinical Interventions in Aging, 2013
- Dysfunctional lung anatomy and small airways degeneration in COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2013
- Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care settingInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- What the pulmonary specialist should know about the new inhalation therapiesEuropean Respiratory Journal, 2011
- Omron NE U22: Comparison Between Vibrating Mesh and Jet NebulizerJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Inspiratory flow rates at different levels of resistance in elderly COPD patientsEuropean Respiratory Journal, 2007
- Use of wet nebulized inhaled respiratory medications under criteria-based reimbursement guidelines in a publicly funded seniors' pharmacare program in Nova Scotia, CanadaThe American Journal of Geriatric Pharmacotherapy, 2007
- Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trialClinical Therapeutics, 2007
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLOS Medicine, 2006